NCT00220818View on ClinicalTrials.gov

A Study to Evaluate the Effect of Lansoprazole on Infants With Gastroesophageal Reflux Disease.

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

July 31, 2005

Study Completion Date

July 31, 2005

Conditions
Gastroesophageal Reflux Disease
Interventions
DRUG

Lansoprazole

Lansoprazole 1.0 mg/kg/day suspension, orally, once daily for up to 5 days.

DRUG

Lansoprazole

Lansoprazole 2.0 mg/kg/day suspension, orally, once daily for up to 5 days.

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY